TheWell Bioscience Introduces VitroGel® NEURON, a Synthetic Hydrogel Enhancing Neuronal Cell Culture

TheWell Bioscience has introduced VitroGel® NEURON, a synthetic and xeno-free hydrogel designed to support both 3D and 2D neuronal cell culture, as well as in vivo delivery applications. This hydrogel platform is engineered to address limitations commonly seen with animal-derived matrices, offering a defined, reproducible, and scalable environment for neuronal growth, differentiation, and network formation.

According to the company, VitroGel® NEURON enables 3D neural stem cell (NSC) differentiation into dopaminergic neurons and promotes neurite and axonal outgrowth. Unlike traditional animal-based extracellular matrices, which typically support only 2D neuron attachment, this synthetic system is formulated to facilitate robust cell–cell and cell–matrix interactions in a variety of neuronal cell types. Applications include neurodevelopmental and neurodegenerative disease modeling, drug screening, and neurotoxicity testing.

The injectable properties of VitroGel® NEURON allow it to function as a carrier for neuron-based cell therapy, spinal cord injury repair, and other regenerative medicine applications.

“After more than five years of dedicated R&D, we are proud to introduce the xeno-free VitroGel® NEURON. To our knowledge, this is the first commercial synthetic hydrogel on the market that can effectively support 3D neuron outgrowth and network formation across a wide spectrum of applications,” said John Huang, Ph.D., CEO of TheWell Bioscience Inc. “We believe this groundbreaking technology will not only provide a reliable and physiologically relevant platform for developing diverse 3D neuronal cell models, but also as a delivery system to advance cell therapy and regenerative medicine to the next level.”

For more details, visit TheWell Bioscience’s website.

Want to keep up on regenerative medicine? Get the weekly newsletter here.

Similar stories

Made Scientific Selected to Manufacture Columbia University’s NOVAKnee, a 3D Printed Knee Replacement Made of Stem Cells and ScaffoldsJun 10, 2026BioStem Technologies Receives 5 Patents for Placental AllograftsMay 20, 2026Kangstem Publishes Promising Phase 1 Results for Cord-Blood Derived Stem Cell Therapy in Knee Osteoarthritis, Post-MRI Data Suggest Potential Cartilage RegenerationMay 19, 2026Royal Biologics and Jellagen Bringing Jellyfish-Derived Collagen Type Zero to the US Regenerative Medicine MarketMay 17, 2026

Editor’s Picks

Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND SoonOct 20, 2026Umbilical Cord Mesenchymal Stem Cell Injections Lower Pain Scores More Than Hyaluronate in 50-Patient Severe Knee Osteoarthritis TrialOct 18, 2026Stempeutics Nabs US Patent for Osteoarthritis Treatment Combining Bone Marrow Stem Cells and Hyaluronic AcidOct 18, 2026Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell TherapyOct 4, 2026